Atea Pharmaceuticals, Inc.

Good afternoon, ladies and gentlemen. Welcome to the ITEA Pharmaceuticals Third Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open up the call for your questions. In order to ask a question, please dial star 11 on your telephone keypad. I will now turn the call over to Janae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Attea Pharmaceuticals. Ms. Barnes, please proceed.

Thank you, Operator. Good afternoon, everyone, and welcome to Attea Pharmaceuticals' third quarter 2022 Financial Results and Business Update conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at irateafarma.com. With me today from Atea, our Chief Executive Officer and Founder, Dr. John Pierre Sommadosi, Chief Development Officer, Dr. Janet Hammond, Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran, and our Chief Commercial Officer, John Zabrica. They will all be available for the Q&A portion of today's call. Before we begin the call, as outlined on slide two, I would like to remind you that today's discussion will contain forward-looking statements that involves risk and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre.

Thank you, Janai. Good afternoon, everyone, and thank you for joining us. We have a number of updates to review with you today that demonstrate the considerable progress we have made so far this year across our three clinical programs. Turning to slide four, as we assess today COVID-19 landscape with the rapid increase in dominance of multiple new variants in different regions of the world, Combined with social dynamics back to near pre-pandemic norms, epidemiologists predict that COVID-19 will persist with multiple waves as we currently see today. The warning durability associated with vaccines and natural infection and the low uptake in the number of people receiving their Omicron booster vaccine with only less than 10% in the U.S. currently, we continue to close large numbers of infected individuals and reinforce the need for new direct acting oral antivirals. Looking forward, as we start enrollment of Sunrise 3, our global Phase 3 registration or trial, these ongoing waves with variants not susceptible to currently available preventive tools should enable timely enrollment of patients for this trial. Pandemic COVID-19 waves can be life-threatening to those at high risk over 65 years old, particularly to those with risk factors causing increased hospitalization and deaths. New all-volunteer valves with improved profile are urgently needed due to the limitations of the current antiviral options. In addition to relapse and safety concerns, the major issue of drug-drug interaction between Paxlovin and commonly prescribed life-saving drugs lead to a major unmet need among patients that are at risk for severe disease. With venifosbuvir, we have the potential to address many of these limitations, and it is our top priority to deliver this direct candidate as fast as possible. Turning to slide five, as SARS-CoV-2 variants continue to splinter, we are confident that Benifazil will remain fully active against ongoing and future new variants based on the consistency potent in vitro antivalent activity that has been demonstrated against variants of concern. Indeed, our most recent dataset demonstrates in vitro antivalent activity against omicron subvariants BA.4 and BA.5, similar to the potency observed with alpha, beta, gamma, epsilon, delta, and omicron subvariants BA.1 and BA.2. I will now turn the call over to John to review the overall anti-viral market opportunity for COVID-19. John?